Clinical Trial

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To assess the efficacy and safety of Almonertinib versus placebo in patients with epidermal growth factor receptor mutation-positive (EGFRm+) stage II-IIIB non-small cell lung cancer (NSCLC), following complete tumor resection with or without adjuvant chemotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-12-28; most recent amendment 2024-11-05.
Status change: Not Yet Recruiting → Active, Not Recruiting 2022-06-13
Trial Details
NCT Number NCT04687241
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Non-small Cell Lung Cancer
Enrollment 192 participants
Start Date 2021-04-30
Primary Completion 2024-07-08 (estimated)
Study Completion 2029-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-07